The addition of enzalutamide to standard of care showed sustained improvement in overall survival for patients with metastatic hormone-sensitive prostate cancer and should be considered as a treatment option for eligible patients.
The addition of enzalutamide to standard of care showed sustained improvement in overall survival for patients with metastatic hormone-sensitive prostate cancer and should be considered as a treatment option for eligible patients.
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy